Cumulus Neuroscience annonce la publication d'un article dans Scientific Reports démontrant que la plateforme NeuLogiq® est viable et utilisable pour l'évaluation cognitive multimodale à domicile chez les personnes atteintes de sclérose latérale amyotrophique (SLA) et de dégénérescence fronto-temporale (DFT)

Data ReadoutpositiveNeuLogiq®Positive

AI Analysis

Summary

Cumulus Neuroscience published results from study CNS-102 in Scientific Reports demonstrating that its NeuLogiq® platform is viable and feasible for multimodal cognitive evaluation at home in patients with ALS and FTD, with 82% of ALS participants finding the platform acceptable.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Study CNS-102 published in Scientific Reports demonstrating NeuLogiq® platform viability for multimodal cognitive assessment at home in ALS and FTD patients; 82% of ALS participants rated the platform as feasible

Importance:5/10

Sentiment:

0.70

neuroscienceALSFTDdigital healthcognitive assessmentpublication

Read the original article

Published by PR Newswire Biotech on August 20, 2026 6:22 AM

Read Original